Category: Psychedelic Bulletin - Page 4 - Psychedelic Alpha

Read more about the article Pα+ Psychedelic Bulletin #163: Tempering Excitement Around Recent Raises; Compass Shares Cut of Open-Label PTSD Data; Other News

Pα+ Psychedelic Bulletin #163: Tempering Excitement Around Recent Raises; Compass Shares Cut of Open-Label PTSD Data; Other News

Post published:May 17, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #162: EQUULUS Therapeutics Emerges from Stealth; Responses to ICER’s Draft Evidence Report on Lykos’ MDMA; and more…

Pα+ Psychedelic Bulletin #162: EQUULUS Therapeutics Emerges from Stealth; Responses to ICER’s Draft Evidence Report on Lykos’ MDMA; and more…

Post published:April 25, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV Ibogaine

Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV Ibogaine

Post published:April 17, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #160: Mutual Recognition for MDMA-AT in the UK? Beckley Shares Cut of 5-MeO-DMT Data; and more

Pα+ Psychedelic Bulletin #160: Mutual Recognition for MDMA-AT in the UK? Beckley Shares Cut of 5-MeO-DMT Data; and more

Post published:March 29, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin

Pα+ Psychedelic Bulletin #159: Patient Access to MDMA-Assisted Therapy; Notes from SXSW; Whole Mushroom vs. Synthetic Psilocybin

Post published:March 21, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #158: Fluence Brings Psychedelic Therapy Training to Ukraine; MindBio’s Microdosing Readout; Biomind’s 5-MeO-DMT Study; and more…

Pα+ Psychedelic Bulletin #158: Fluence Brings Psychedelic Therapy Training to Ukraine; MindBio’s Microdosing Readout; Biomind’s 5-MeO-DMT Study; and more…

Post published:March 6, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #157: Psilocybin for Generalised Anxiety Disorder; Uptick in Psilocybin-Related Poison Centre Calls

Pα+ Psychedelic Bulletin #157: Psilocybin for Generalised Anxiety Disorder; Uptick in Psilocybin-Related Poison Centre Calls

Post published:March 1, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

Post published:February 19, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer Experiential Training for MDMA Therapists

Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer Experiential Training for MDMA Therapists

Post published:February 8, 2024
Post category:Psychedelic Bulletin Pα+

Read more about the article Pα+ Psychedelic Bulletin #154: Public & Industry Respond to DEA’s Renewed DOI and DOC Scheduling Plan; TARA Mind Scores $8m Seed; Updates on State Psychedelics Programs

Pα+ Psychedelic Bulletin #154: Public & Industry Respond to DEA’s Renewed DOI and DOC Scheduling Plan; TARA Mind Scores $8m Seed; Updates on State Psychedelics Programs

Post published:January 26, 2024
Post category:Psychedelic Bulletin Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.